Monte Rosa Therapeutics (GLUE) EBT (2020 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly EBT of -$44.5 million in Q1 2026, down 51.04% quarter-over-quarter from -$29.4 million in Q4 2025, and down 193.18% on a YoY basis from $47.7 million in Q1 2025.
Monte Rosa Therapeutics (GLUE) EBT (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$44.5 million for Q1 2026.
- In Q1 2026, EBT fell 193.18% year-over-year to -$44.5 million; the TTM figure through Mar 2026 stood at -$115.2 million (down 1317.87% YoY), while the FY2025 annual figure was -$23.1 million, up 67.09% from the prior year.
- EBT was -$44.5 million for Q1 2026 at Monte Rosa Therapeutics, down from -$29.4 million in the prior quarter.
- In the past five years, EBT ranged from a high of $47.7 million in Q1 2025 to a low of -$44.5 million in Q1 2026.
- Historically, EBT has averaged -$22.4 million across 5 years, with a median of -$30.1 million in 2024.
- Biggest YoY gain for EBT was 249.62% in 2025; the steepest drop was 288.64% in 2025.
- A 5-year view of EBT shows it stood at -$30.8 million in 2022, then dropped by 8.1% to -$33.3 million in 2023, then surged by 146.89% to $15.6 million in 2024, then slumped by 288.64% to -$29.4 million in 2025, then sank by 51.04% to -$44.5 million in 2026.
- The last three EBT figures came in at -$44.5 million (Q1 2026), -$29.4 million (Q4 2025), and -$30.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -44.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.45 Mn |
| Dec 31, 2025 | -29.43 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -11.10 Mn |
| Mar 31, 2025 | 47.71 Mn |
| Dec 31, 2024 | 15.60 Mn |
| Sep 30, 2024 | -23.79 Mn |
| Jun 30, 2024 | -30.06 Mn |
| Mar 31, 2024 | -31.89 Mn |
| Dec 31, 2023 | -33.27 Mn |
| Sep 30, 2023 | -34.71 Mn |
| Jun 30, 2023 | -34.99 Mn |
| Mar 31, 2023 | -32.04 Mn |
| Dec 31, 2022 | -30.78 Mn |
| Sep 30, 2022 | -27.32 Mn |
| Jun 30, 2022 | -26.47 Mn |
| Mar 31, 2022 | -24.15 Mn |
| Dec 31, 2021 | -23.37 Mn |
| Sep 30, 2021 | -19.86 Mn |
| Jun 30, 2021 | -18.11 Mn |